Format

Send to:

Choose Destination
See comment in PubMed Commons below
Proc Natl Acad Sci U S A. 2014 Sep 16;111(37):13481-6. doi: 10.1073/pnas.1412420111. Epub 2014 Sep 2.

Clearance of pathological antibodies using biomimetic nanoparticles.

Author information

  • 1Department of Nanoengineering, Moores Cancer Center, and.
  • 2Department of Nanoengineering, Department of Ophthalmology and Shiley Eye Center, University of California, San Diego, La Jolla, CA 92093.
  • 3Department of Nanoengineering, Moores Cancer Center, and zhang@ucsd.edu.

Abstract

Pathological antibodies have been demonstrated to play a key role in type II immune hypersensitivity reactions, resulting in the destruction of healthy tissues and leading to considerable morbidity for the patient. Unfortunately, current treatments present significant iatrogenic risk while still falling short for many patients in achieving clinical remission. In the present work, we explored the capability of target cell membrane-coated nanoparticles to abrogate the effect of pathological antibodies in an effort to minimize disease burden, without the need for drug-based immune suppression. Inspired by antibody-driven pathology, we used intact RBC membranes stabilized by biodegradable polymeric nanoparticle cores to serve as an alternative target for pathological antibodies in an antibody-induced anemia disease model. Through both in vitro and in vivo studies, we demonstrated efficacy of RBC membrane-cloaked nanoparticles to bind and neutralize anti-RBC polyclonal IgG effectively, and thus preserve circulating RBCs.

KEYWORDS:

autoantibody; immune therapy; nanomedicine; type II hypersensitivity reaction

PMID:
25197051
[PubMed - indexed for MEDLINE]
PMCID:
PMC4169917
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Write to the Help Desk